Merck Can't Dodge Fraud Case Over Vytorin Trials
Merck & Co Inc. on Wednesday lost its bid to dismiss separate complaints of four institutional funds claiming it misrepresented results of a clinical trial of its anti-cholesterol drug Vytorin, when...To view the full article, register now.
Already a subscriber? Click here to view full article